Cargando…

Lipoprotein(a), Immune Cells and Cardiovascular Outcomes in Patients with Premature Coronary Heart Disease

The detection of lipoprotein(a) [Lp(a)] in the artery wall at the stage of lipid-bands formation may indicate that it participates in the atherosclerosis local nonspecific inflammatory process. Innate immune cells are involved in atherogenesis, with monocytes playing a major role in the initiation o...

Descripción completa

Detalles Bibliográficos
Autores principales: Afanasieva, Olga I., Tyurina, Alexandra V., Klesareva, Elena A., Arefieva, Tatiana I., Ezhov, Marat V., Pokrovsky, Sergei N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8876319/
https://www.ncbi.nlm.nih.gov/pubmed/35207757
http://dx.doi.org/10.3390/jpm12020269
_version_ 1784658140886728704
author Afanasieva, Olga I.
Tyurina, Alexandra V.
Klesareva, Elena A.
Arefieva, Tatiana I.
Ezhov, Marat V.
Pokrovsky, Sergei N.
author_facet Afanasieva, Olga I.
Tyurina, Alexandra V.
Klesareva, Elena A.
Arefieva, Tatiana I.
Ezhov, Marat V.
Pokrovsky, Sergei N.
author_sort Afanasieva, Olga I.
collection PubMed
description The detection of lipoprotein(a) [Lp(a)] in the artery wall at the stage of lipid-bands formation may indicate that it participates in the atherosclerosis local nonspecific inflammatory process. Innate immune cells are involved in atherogenesis, with monocytes playing a major role in the initiation of atherosclerosis, while neutrophils can contribute to plaque destabilization. This work studies the relationship between Lp(a), immune blood cells and major adverse cardiovascular events (MACE) in patients with the early manifestation of coronary heart disease (CHD). The study included 200 patients with chronic CHD, manifested up to the age of 55 in men and 60 in women. An increased Lp(a) concentration [hyperLp(a)] was shown to predict cardiovascular events in patients with premature CHD with long-term follow-up. According to the logistic regression analysis results, an increase in the monocyte count with OR = 4.58 (95% CI 1.04–20.06) or lymphocyte-to-monocyte ratio with OR = 0.82 (0.68–0.99), (p < 0.05 for both) was associated with MACE in patients with early CHD, regardless of gender, age, classical risk factors, atherogenic lipoproteins concentration and statin intake. The combination of an increased monocyte count and hyperLp(a) significantly increased the proportion of patients with early CHD with subsequent development of MACE (p = 0.02, p (trend) = 0.003). The odds of cardiovascular events in patients with early CHD manifestation were highest in patients with an elevated lymphocyte-to-monocyte ratio and an elevated Lp(a) level. A higher neutrophil blood count and an elevated neutrophil-to-lymphocyte ratio determined the faster development of MACE in patients with a high Lp(a) concentration. The data obtained in this study suggest that the high atherothrombogenicity of Lp(a) is associated with the “inflammatory” component and the innate immune cells involvement in this process. Thus, the easily calculated immunological ratios of blood cells and Lp(a) concentrations can be considered simple predictors of future cardiovascular events.
format Online
Article
Text
id pubmed-8876319
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88763192022-02-26 Lipoprotein(a), Immune Cells and Cardiovascular Outcomes in Patients with Premature Coronary Heart Disease Afanasieva, Olga I. Tyurina, Alexandra V. Klesareva, Elena A. Arefieva, Tatiana I. Ezhov, Marat V. Pokrovsky, Sergei N. J Pers Med Article The detection of lipoprotein(a) [Lp(a)] in the artery wall at the stage of lipid-bands formation may indicate that it participates in the atherosclerosis local nonspecific inflammatory process. Innate immune cells are involved in atherogenesis, with monocytes playing a major role in the initiation of atherosclerosis, while neutrophils can contribute to plaque destabilization. This work studies the relationship between Lp(a), immune blood cells and major adverse cardiovascular events (MACE) in patients with the early manifestation of coronary heart disease (CHD). The study included 200 patients with chronic CHD, manifested up to the age of 55 in men and 60 in women. An increased Lp(a) concentration [hyperLp(a)] was shown to predict cardiovascular events in patients with premature CHD with long-term follow-up. According to the logistic regression analysis results, an increase in the monocyte count with OR = 4.58 (95% CI 1.04–20.06) or lymphocyte-to-monocyte ratio with OR = 0.82 (0.68–0.99), (p < 0.05 for both) was associated with MACE in patients with early CHD, regardless of gender, age, classical risk factors, atherogenic lipoproteins concentration and statin intake. The combination of an increased monocyte count and hyperLp(a) significantly increased the proportion of patients with early CHD with subsequent development of MACE (p = 0.02, p (trend) = 0.003). The odds of cardiovascular events in patients with early CHD manifestation were highest in patients with an elevated lymphocyte-to-monocyte ratio and an elevated Lp(a) level. A higher neutrophil blood count and an elevated neutrophil-to-lymphocyte ratio determined the faster development of MACE in patients with a high Lp(a) concentration. The data obtained in this study suggest that the high atherothrombogenicity of Lp(a) is associated with the “inflammatory” component and the innate immune cells involvement in this process. Thus, the easily calculated immunological ratios of blood cells and Lp(a) concentrations can be considered simple predictors of future cardiovascular events. MDPI 2022-02-12 /pmc/articles/PMC8876319/ /pubmed/35207757 http://dx.doi.org/10.3390/jpm12020269 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Afanasieva, Olga I.
Tyurina, Alexandra V.
Klesareva, Elena A.
Arefieva, Tatiana I.
Ezhov, Marat V.
Pokrovsky, Sergei N.
Lipoprotein(a), Immune Cells and Cardiovascular Outcomes in Patients with Premature Coronary Heart Disease
title Lipoprotein(a), Immune Cells and Cardiovascular Outcomes in Patients with Premature Coronary Heart Disease
title_full Lipoprotein(a), Immune Cells and Cardiovascular Outcomes in Patients with Premature Coronary Heart Disease
title_fullStr Lipoprotein(a), Immune Cells and Cardiovascular Outcomes in Patients with Premature Coronary Heart Disease
title_full_unstemmed Lipoprotein(a), Immune Cells and Cardiovascular Outcomes in Patients with Premature Coronary Heart Disease
title_short Lipoprotein(a), Immune Cells and Cardiovascular Outcomes in Patients with Premature Coronary Heart Disease
title_sort lipoprotein(a), immune cells and cardiovascular outcomes in patients with premature coronary heart disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8876319/
https://www.ncbi.nlm.nih.gov/pubmed/35207757
http://dx.doi.org/10.3390/jpm12020269
work_keys_str_mv AT afanasievaolgai lipoproteinaimmunecellsandcardiovascularoutcomesinpatientswithprematurecoronaryheartdisease
AT tyurinaalexandrav lipoproteinaimmunecellsandcardiovascularoutcomesinpatientswithprematurecoronaryheartdisease
AT klesarevaelenaa lipoproteinaimmunecellsandcardiovascularoutcomesinpatientswithprematurecoronaryheartdisease
AT arefievatatianai lipoproteinaimmunecellsandcardiovascularoutcomesinpatientswithprematurecoronaryheartdisease
AT ezhovmaratv lipoproteinaimmunecellsandcardiovascularoutcomesinpatientswithprematurecoronaryheartdisease
AT pokrovskysergein lipoproteinaimmunecellsandcardiovascularoutcomesinpatientswithprematurecoronaryheartdisease